drugset / Trial / NCT03038516

'Palliative-D' Vitamin D to Palliative Cancer Patients

NCT03038516

Phase 2 Completed 244 enrolled Region Stockholm
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients can decrease opioid consumption, fatigue and infectious burden and increase quality of life.

Timeline

Start
2017-11-01
Primary completion
2020-06-09
Completion
2020-06-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cholecalciferol Other / unclassified 4000 iu Oral

Indications